期刊文献+

乳腺癌新辅助化疗过程中18F-FDGPET-CT与化疗前Ki-67、COX-2表达的相关性研究 被引量:1

The correlation analysis between 18F-FDG PET-CT in breast cancer with neoadjuvant chemotherapy and the expression of Ki-67 and COX-2 before neoadjuvant chemotherapy
原文传递
导出
摘要 目的研究乳腺癌新辅助化疗过程中mF—FDGPET—CT的病灶最大标准化摄取值(SUVmax)的变化与其化疗前Ki-67(一种增殖细胞核抗原)、环氧合酶2(COX-)表达的相关性。方法初治乳腺癌患者19例,在新辅助化疗前、第1疗程结束后及第2疗程结束后分别行18F—FDGPET—CT,并计算病灶的SUVmax变化率,在新辅助化疗前取患者乳腺肿瘤组织标本进行Ki-67、COX-2免疫组化检查,并比较不同Ki-67和COX-2表达组之间的suvmax变化率。结果新辅助化疗前、第1疗程及第2疗程结束后的SUVmax变化率在化疗前Ki-67、COX-2不同表达组之间差异均无统计学意义。结论化疗前Ki-67、COX-2的表达情况无法充分解释病灶在新辅助化疗过程中18F-FDG的摄取变化,而其最有可能的解释是细胞之间复杂的能源需求与肿瘤微环境的相互作用。 Objective To study the expression of Ki-67 (a kind of proliferation cell nuclear antigen), cyclooxygenase-2 (COX-2) in breast cancer befbre neoadjuvant chemotherapy, and its correlation with the changes of maximum standarded uptake value (SUV). Methods In a prospertive trial, ISF-FDG PET-CT were performed in 19 women with primary breast cancer before and after the first and second cycle of neoadjuvant chemotherapy respectively, the changes of SUVmax were computered. Divided the patients into ditterent groups according to the Ki-67 and COX-2 expression, then compared the rate of change of SUVmax in different groups. Results There was no correlation between the changes of SUVmax, after chemotherapy and the expression of Ki-67, COX-2 before neoadjuvant chemotherapy. Conclusions The expression of Ki-67 and COX-2 before neoadjuvant chemotherapy were unable to sufficiently explain the changes of 18F-FDG uptake during the chemotherapy process. The metabolic changes were most likely explained by a complex interaction between cellular energy demand and tumoral microenvironment.
出处 《国际放射医学核医学杂志》 2011年第4期238-240,共3页 International Journal of Radiation Medicine and Nuclear Medicine
关键词 乳腺肿瘤 化学疗法 辅助 KI-67抗原 环氧合酶2 正电子发射断层显像术 体层摄影术 X线计算机 Breast neoplasms Chemotherapy, adjuvant Ki-67 antigen Cycloocygenase 2 Positron- emission tomography Tomography, X-ray computed
  • 相关文献

参考文献10

  • 1Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet, 2003, 362(9381): 362-369.
  • 2林其声,施雄文,徐书楷,蒋新宇.新辅助化疗对乳腺癌ki67、cox-2、p53表达的影响及其临床意义[J].中国当代医药,2009,16(24):13-14. 被引量:17
  • 3McDermott GM, Welch A, Staff RT, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat, 2007, 102(1): 75-84.
  • 4Sehwarz-Dose J, Untch M, Tiling R, et al. Monitoring primary systemic therapy of large and locally advanced breast eaneer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglueose. J Clin Oncol, 2009, 27(4): 535-541.
  • 5温广华,冯彦林,黄克敏,余丰文,刘德军,袁建伟,杨明.乳腺癌^(18)F-FDG PET/CT标准化摄取值与Ki-67表达关系的初步研究[J].中国临床医学影像杂志,2010,21(7):509-511. 被引量:5
  • 6何仲琴,李恩孝.环氧化酶-2表达与肿瘤关系的研究进展[J].现代肿瘤医学,2005,13(4):573-575. 被引量:9
  • 7Ruibal A, Abdulkader I, Gude F, et al. The immunohistochemical expression of cyclooxygenase 2 is inversely associated with 18F- FDG-PET SUV values in non-small-cell lung cancers. Initial results. Rev Esp Med Nucl, 2009, 28(1): 11-14.
  • 8Surowiak P, Materna V, Matkowski R, et al. Relationship between the expression of cyclooxygenase 2 and MDRl/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res, 2005, 7(5): R862-R870.
  • 9Denkert C, Winzer KJ, Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer, 2004, 4(6): 428-433.
  • 10Zhao X, Goswami M, Pokhriyal N, et al. Cyclooxygenase-2 expres- sion during immortalization and breast caneer progression. Caneer Res, 2008, 68(2): 467-475.

二级参考文献34

共引文献28

同被引文献2

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部